Organ-on-a-Chip (OOC) is gaining attention as an innovative biotechnology that can reduce animal testing. This technology involves culturing human cells and tissues on a microfluidic chip, mimicking the functions of human organs. These chips have the advantage of being able to analyze drug toxicity, efficacy, and various physiological responses in real-time, potentially replacing animal experiments in the drug development process. OOC technology is particularly highlighted as a practical alternative to animal testing in the pharmaceutical and life sciences fields.

A real-world application example is the American biotech company Emulate. Emulate has developed technologies such as Liver-on-a-Chip and Lung-on-a-Chip, helping pharmaceutical companies evaluate drug toxicity and safety in the early stages of new drug development. This technology is being used in collaboration with the FDA as a method to replace animal testing in the new drug approval process. In fact, major pharmaceutical companies like Johnson & Johnson and AstraZeneca are using Emulate’s organ-on-chip systems to replace animal testing in their drug development processes. This technology can accurately predict drug reactions in the human body, providing more reliable results than animal experiments, while also contributing to time and cost savings.

Another example is the multi-organ-on-chip system developed by TissUse in Germany. This system connects multiple organs, allowing for the evaluation of complex inter-organ interactions. For instance, it can simultaneously analyze the effects of a drug on the liver, kidneys, and heart by connecting these organs. This significantly contributes to reducing the need for animal testing in complex drug metabolism studies.
These OOC technologies are establishing themselves as important alternative technologies that can address both ethical issues and the inefficiencies of animal testing. It is expected that with further research and commercialization, the range of applications in the biohealth field will expand in the future.